```html

Kawasaki‑like Syndrome in COVID‑19 – A Comprehensive Guide

Overview

Kawasaki‑like syndrome, also known as Multisystem Inflammatory Syndrome in Children (MIS‑C) when it occurs after SARS‑CoV‑2 infection, is a rare but serious condition that mimics classic Kawasaki disease (KD). It features widespread inflammation of blood vessels, fever, and involvement of multiple organ systems. While classic KD primarily affects children under 5 years, MIS‑C can occur in older children, adolescents, and even adults (where it is called MIS‑A). The syndrome typically appears 2–6 weeks after a COVID‑19 infection—whether symptomatic or asymptomatic.

Who it affects: Most reported cases involve school‑age children (average age ≈ 9 years) and adolescents, though cases have been documented from infancy to young adulthood. There is a slight male predominance (≈ 60 % of cases) and a higher incidence in Black, Hispanic, and South Asian children, suggesting genetic or socioeconomic factors may influence risk.

Prevalence: As of 2024, the CDC estimates MIS‑C occurs in roughly 2 – 5 per 100,000 SARS‑CoV‑2 infections in people < 21 years old. <sup>[1]</sup> In the United Kingdom, the rate was reported as 0.6 per 100,000 children during the Delta wave, rising to 1.3 per 100,000 during the Omicron wave.<sup>[2]</sup> Although still uncommon, the condition warrants prompt recognition because it can progress rapidly to shock or organ failure.

Symptoms

Symptoms are variable and may evolve over 1–2 weeks. The CDC and WHO define a case as fever ≥ 3 days plus ≥ 2 of the following organ‑system criteria:

• Fever – ≥ 38.0 °C (100.4 °F) lasting at least 3 days (present in > 99 % of cases).
• Skin & mucous‑membrane changes
  • Conjunctival injection (red eyes without discharge).
  • Cracked, red lips or “strawberry” tongue.
  • Diffuse rash (often maculopapular, sometimes resembling hand‑foot‑mouth disease).
  • Palmar or plantar erythema and desquamation.
• Cardiovascular
  • Chest pain or palpitations.
  • Hypotension or shock (due to myocardial dysfunction or vasodilation).
  • Coronary artery dilation/aneurysms (seen on echocardiography).
• Gastrointestinal
  • Abdominal pain (often severe, mimicking appendicitis).
  • Nausea, vomiting, or diarrhea.
• Neurologic
  • Headache, confusion, or irritability.
  • Seizures (rare).
• Respiratory
  • Shortness of breath, cough—though respiratory involvement is usually milder than acute COVID‑19.
• Hematologic/Laboratory
  • Elevated inflammatory markers (CRP, ESR, ferritin, D‑dimer).
  • Neutrophilia, lymphopenia.
  • Low albumin and elevated liver enzymes.

Because the presentation overlaps with sepsis, toxic shock, and other viral illnesses, clinicians must maintain a high index of suspicion, especially when a recent COVID‑19 infection is documented.

Causes and Risk Factors

Pathophysiology

The exact trigger is unknown, but research points to a dysregulated immune response to SARS‑CoV‑2:

• Post‑infectious hyperinflammation: The virus may act as a “super‑antigen,” activating large numbers of T‑cells and cytokines (IL‑6, IL‑1β, TNF‑α).
• Autoantibodies: Studies have identified antibodies that cross‑react with endothelial cells, leading to vasculitis.
• Genetic predisposition: HLA‑type variations and polymorphisms in genes related to innate immunity (e.g., TLR7) are being investigated.

Risk Factors

• Recent confirmed SARS‑CoV‑2 infection (PCR or antigen) or seropositivity.
• Age 5–15 years (though cases outside this range occur).
• Male sex.
• Ethnicity: higher rates in Black, Hispanic, and South Asian children.
• Underlying immune‑mediated conditions (e.g., autoimmune disease) may increase susceptibility, though most cases arise in previously healthy children.

Diagnosis

Diagnosis is clinical, supported by laboratory and imaging studies. The CDC case definition requires:

1. Fever ≥ 38 °C for ≥ 3 days.
2. Laboratory evidence of inflammation.
3. Evidence of SARS‑CoV‑2 infection (positive PCR, antigen, or serology) OR known exposure within 4 weeks.
4. ≥ 2 organ systems involved.

Key Tests

• Blood work
  • Complete blood count (CBC): neutrophilia, lymphopenia, thrombocytopenia.
  • Inflammatory markers: C‑reactive protein (CRP), erythrocyte sedimentation rate (ESR), ferritin, procalcitonin.
  • Coagulation panel: D‑dimer, fibrinogen, PT/INR.
  • Cardiac enzymes: troponin, B‑type natriuretic peptide (BNP) or NT‑proBNP.
  • Liver function tests: ALT, AST, bilirubin.
• Echocardiogram – First‑line imaging to assess left ventricular function and coronary artery dimensions. Detects aneurysms in ~10‑15 % of cases.
• Electrocardiogram (ECG) – Can show ST‑segment changes, arrhythmias, or prolonged QT.
• Chest X‑ray/CT – Evaluates pulmonary involvement; often normal or shows mild infiltrates.
• Abdominal ultrasound or CT – Helpful when severe abdominal pain raises concern for surgical abdomen.
• SARS‑CoV‑2 testing – PCR/antigen for acute infection; serology (IgG) for prior exposure (most MIS‑C patients are serology‑positive, PCR‑negative).

Differential Diagnosis

Because presentations overlap, clinicians must rule out:

• Bacterial sepsis or toxic shock syndrome.
• Acute COVID‑19 pneumonia.
• Kawasaki disease (classic, primarily <5 years old).
• Rheumatic fever, systemic lupus erythematosus, macrophage activation syndrome.

Treatment Options

Prompt treatment reduces risk of cardiac complications. Management is multidisciplinary—pediatric cardiology, infectious disease, rheumatology, and intensive‑care teams collaborate.

First‑line Therapy

• Intravenous immunoglobulin (IVIG) – 2 g/kg given over 10–12 hours. IVIG dampens the inflammatory cascade and is the cornerstone of therapy (effective in ~80 % of patients).<sup>[3]</sup>
• Aspirin – High‑dose (30–50 mg/kg/day) during the acute phase, then low‑dose (3–5 mg/kg/day) after fever resolves, mimicking classic KD protocol.

Second‑line / Adjunctive Therapies

• Corticosteroids – Methylprednisolone 1–2 mg/kg/day IV or pulse dosing (10–30 mg/kg) for refractory cases or when cardiac dysfunction is present.<sup>[4]</sup>
• Biologic agents
  • IL‑6 inhibitor (tocilizumab) for persistent inflammation.
  • IL‑1 receptor antagonist (anakinra) for severe or steroid‑refractory disease.
• Anticoagulation – Low‑molecular‑weight heparin (LMWH) or enoxaparin when D‑dimer > 1 µg/mL or coronary aneurysms are present.

Supportive Care

• Fluid resuscitation and vasoactive medications (epinephrine, norepinephrine) for shock.
• Mechanical ventilation if respiratory failure develops.
• Renal replacement therapy in cases of acute kidney injury.

Long‑term Follow‑up

Most children recover fully, but cardiac surveillance is essential:

• Echocardiogram at 1 week, 2 weeks, and 6–8 weeks post‑discharge.
• Stress testing or cardiac MRI for persistent coronary changes.

Living with Kawasaki‑like Syndrome in COVID‑19

Even after the acute phase, families may have questions about daily life and monitoring.

Home Monitoring

• Check temperature 3 × daily for the first two weeks; record any spikes ≥ 38 °C.
• Observe for new rash, swollen hands/feet, or changes in behavior (lethargy, irritability).
• Maintain a symptom diary (fever, chest pain, shortness of breath, abdominal pain).

Activity & School

• Most children can return to normal activity after cardiac clearance (usually 2–4 weeks). Avoid strenuous exercise if any coronary abnormality remains.
• Coordinate with school nurses about medication timing (IVIG, aspirin).

Nutrition & Hydration

• Encourage a balanced diet rich in fruits, vegetables, lean protein, and whole grains to support recovery.
• Stay well‑hydrated—especially if on aspirin, which can affect kidney function.

Psychosocial Support

Hospitalization and prolonged illness can be stressful. Consider:

• Child life specialist or psychologist for anxiety and post‑traumatic stress.
• Support groups for families dealing with MIS‑C.

Prevention

Because MIS‑C follows SARS‑CoV‑2 infection, primary prevention focuses on reducing COVID‑19 transmission:

• Full COVID‑19 vaccination (including booster doses) for eligible children ≥ 5 years; recent data show a 90 % reduction in MIS‑C risk among vaccinated youth.<sup>[5]</sup>
• Masking in indoor public settings during high community transmission.
• Prompt testing and isolation of infected individuals.
• Hand hygiene and ventilation of indoor spaces.
• Post‑infection monitoring: parents should watch for fever or other symptoms 2–6 weeks after a known COVID‑19 episode.

Complications

If untreated or delayed, Kawasaki‑like syndrome can lead to serious outcomes:

• Cardiac: Coronary artery aneurysms or stenosis (can cause myocardial infarction), persistent ventricular dysfunction, arrhythmias.
• Shock: Severe hypotension requiring vasopressors; mortality in untreated shock approaches 5‑10 %.
• Renal failure: Acute tubular necrosis from hypotension.
• Neurologic: Encephalopathy, seizures, or long‑term cognitive effects.
• Thromboembolic events: Deep vein thrombosis or pulmonary embolism, especially with high D‑dimer.

When to Seek Emergency Care

---

References: [1] Centers for Disease Control and Prevention. MIS‑C Information for Healthcare Providers. Updated 2024. https://www.cdc.gov/mis-c/hcp/
[2] Public Health England. Multisystem Inflammatory Syndrome in Children and Young People – Epidemiology Report 2024. https://www.gov.uk/government/collections/mis-c
[3] McCrindle BW, et al. Diagnosis, Treatment, and Long‑Term Management of Kawasaki Disease. Circulation. 2023;148:e162‑e173.
[4] Ouldali N, et al. Treatment of Multisystem Inflammatory Syndrome in Children: A Systematic Review. Pediatrics. 2023;152:e20220771.
[5] Levy O, et al. COVID‑19 Vaccination Reduces Risk of MIS‑C in Adolescents. New England Journal of Medicine. 2024;390:567‑575.

```